Cancer Pain

Orphan Medical licenses rights to pain product

Published in Proteomics Weekly, June 10th, 2002

Orphan Medical, Inc. (ORPH) announced that it has both licensed patent rights and acquired certain data relating to butamben (butyl-p-aminobenzoate) suspension.

The company will investigate butamben as a supplement to opiate analgesia treatment for intractable cancer pain. Initiation of a full development program will depend on the outcome of the company's continuing market research and development assessment of the product.

In addition to licensing worldwide rights under two patents, the company has acquired preclinical and early clinical data. In these studies, a series of epidurally delivered butamben appeared to be highly selective in blocking...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Proteomics Weekly

Source: Proteomics Weekly (2002-06-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry